Webcasts
Watch these videos and webcasts to get helpful information on living with CF. Be sure to visit this page in the future, too, as new videos are added regularly.
To find out more about the videos on this page, click on the photo or the title. You can also scroll down the page to reach them, too.
Why Appearing Healthy Is Only Part of the Story
BACK TO TOP
Establishing an early CF management plan is important, even when no CF symptoms are present. In this webcast, Dr. Barbara Chatfield, MD, and Natalie Brown discuss why establishing a management plan is important from both the professional and parental perspectives. Dr. Chatfield is a pediatric pulmonologist and a professor of pediatrics at the University of Utah, and Natalie Brown is a mother of twins who were diagnosed with CF at birth.
You can follow along with the presentation with slides that are timed to correspond with the video.
7-Question Survey
Thank You For Watching the Webcast!
On behalf of Dr. Barbara Chatfield, CF caregiver Natalie Brown, and Genentech, let us express our appreciation for your interest in our webcast.
Please let us know what you thought about the webcast by completing the survey below.
Also, let us know if you have any questions that were not answered during the webcast.
Your feedback is important, and will help us make sure future webcasts continue to be valuable to you.
Thank you for watching and completing this survey.
Please continue to navigate on CFLiving.com for additional resources.
Living with CF
BACK TO TOP
We feel that hearing from doctors, parents, and patients who deal with CF provides information that others in similar situations may find helpful. In this webcast, Dr. Susanna McColley, MD, talks about various treatment options that are available for pediatric patients who have CF. Kelly Weber and her son, Jake, talk about the treatments that they use daily to take care of his CF. Dr. McColley is the director of the CF Center at Children’s Memorial Hospital and associate professor of pediatrics at Northwestern University.
Close X
Important Safety Information
Contraindications
Pulmozyme should not be used in patients who are allergic to any of its ingredients. Pulmozyme should be used in conjunction with standard therapies for CF.
Adverse Reactions
When starting Pulmozyme therapy, patients may experience change in or loss of voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose. These side effects are usually mild and short-lived.
Pediatric Use
There is a limited amount of information available concerning the usage of Pulmozyme in patients who are younger than 5 years. The decision to use Pulmozyme in these patients is made after considering the potential for a benefit in lung function or in decreasing the risk of RTEs.
Important Safety Considerations
The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to ≤10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. There were more reports of cough, moderate to severe cough, runny nose, and rash in the younger group of patients. Other reported events tended to be of mild to moderate severity. The kind of side effects reported was similar to that of Pulmozyme when used in the larger trials that studied older patients.
For further information, please see the Pulmozyme full prescribing information. If you have questions, please discuss them with your CF healthcare team.
Managing Your Care as an Adult
BACK TO TOP
CF treatment administration changes as the patient gets older. In pediatric patients, parental involvement is important to manage a treatment plan, but adult patients have more responsibility to administer treatment on their own. In this webcast, Casey Flaherty talks about how she made the switch from pediatric to adult care. She talks with her mom and doctor about suggestions for taking care of CF as one becomes more independent.
Close X
Important Safety Information
Contraindications
Pulmozyme should not be used in patients who are allergic to any of its ingredients. Pulmozyme should be used in conjunction with standard therapies for CF.
Adverse Reactions
When starting Pulmozyme therapy, patients may experience change in or loss of voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose. These side effects are usually mild and short-lived.
Pediatric Use
There is a limited amount of information available concerning the usage of Pulmozyme in patients who are younger than 5 years. The decision to use Pulmozyme in these patients is made after considering the potential for a benefit in lung function or in decreasing the risk of RTEs.
Important Safety Considerations
The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to ≤10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. There were more reports of cough, moderate to severe cough, runny nose, and rash in the younger group of patients. Other reported events tended to be of mild to moderate severity. The kind of side effects reported was similar to that of Pulmozyme when used in the larger trials that studied older patients.
For further information, please see the Pulmozyme full prescribing information. If you have questions, please discuss them with your CF healthcare team.
Indication and Usage
Daily administration of Pulmozyme® (dornase alfa) Inhalation Solution along with standard therapies is indicated in the management of cystic fibrosis patients to improve lung function. In patients with a forced vital capacity (volume of air exhaled with maximum effort and speed) greater than or equal to 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring the administration of injectable antibiotics. In our pivotal study, safety and efficacy of daily administration has not been studied in patients beyond 12 months.
Important Safety Information
Pulmozyme should not be used in patients who are allergic to any of its
ingredients
Pulmozyme should be used along with standard therapies for cystic fibrosis
When starting Pulmozyme therapy, patients may experience change in or loss of their voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose
These side effects are usually mild and short-lived
The effect of Pulmozyme on exercise tolerance has not been established in adults and children
For further information, please see the Pulmozyme full prescribing information. If you have questions, please discuss them with your CF healthcare team.
